BioRestorative Therapies delays Q3 filing as audits remain incomplete
BRTX•BioRestorative Therapies said it will miss the deadline, including a five-day extension, for its September 30, 2026, Form 10-Q. Its June 30, 2026, Form 10-Q also remains unfiled while new audits for 2024 and 2025 are completed.
1. Filings remain delayed
BioRestorative Therapies said Bush & Associates CPA must complete new audits for 2024 and 2025 before it can finish interim financial statement reviews. The company said results for the three and nine months ended September 30 could differ materially from 2025, amid suspended product sales and advisory expenses. Orders and shipments of its biocosmeceutical products were suspended August 7, 2026, pending a business and regulatory review.




